G
Glenn M. Chertow
Researcher at Stanford University
Publications - 830
Citations - 94517
Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.
Papers
More filters
Journal ArticleDOI
Removing Disincentives to Kidney Donation: A Quantitative Analysis.
Journal Article
Olecranon bursitis caused by infection with Candida lusitaniae.
Samuel M. Behar,Glenn M. Chertow +1 more
TL;DR: A 59-year-old woman with diabetes and chronic asthma treated with prednisone and methotrexate who developed chronic olecranon bursitis caused by Candida lusitaniae is described, which ultimately died of a Pneumocystis carinii infection.
Journal ArticleDOI
Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.
Vasily Belozeroff,Glenn M. Chertow,Christopher N. Graham,Bastian Dehmel,Patrick S. Parfrey,Andrew Briggs +5 more
TL;DR: In the unadjusted ITT analysis, cinacalcet does not represent a cost- effective use of health care resources when applying a willingness-to-pay threshold of $100,000 per QALY.
Journal ArticleDOI
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD.
James H. Lewis,Michel Jadoul,Geoffrey A. Block,Melanie P. Chin,Deborah A. Ferguson,Angie Goldsberry,Colin J. Meyer,Megan O'Grady,Pablo E. Pergola,Scott A. Reisman,W. Christian Wigley,Glenn M. Chertow +11 more
TL;DR: The data suggest that the increases in ALT and AST observed clinically were, at least in part, related to the pharmacological induction of aminotransferases via Nrf2 activation, rather than to any intrinsic form of hepatotoxicity.
Journal ArticleDOI
Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease–Related Medications in Veterans
Shen Song,I-Chun Thomas,Calyani Ganesan,Ericka Sohlberg,Glenn M. Chertow,Joseph C. Liao,Joseph C. Liao,Simon L. Conti,Simon L. Conti,Christopher S. Elliott,Christopher S. Elliott,Alan C. Pao,Alan C. Pao,John T. Leppert,John T. Leppert +14 more
TL;DR: Clinicians adjust their treatment regimens in response to 24-hour urine testing by increasing the prescription of medications thought to reduce risk for urinary stone disease.